大剂量复方苦参注射液联合化疗治疗晚期非小细胞肺癌疗效观察  

Efficacy of Large Dose of Compound Matrine Injection Combined Chemotherapy for Non-Small-Cell Lung Cancer

作　　者：于振刚[1] 王炳辙[1] 

机构地区：[1]潍坊市人民医院呼吸内科,山东潍坊261041

出　　处：《中国医院用药评价与分析》2012年第2期149-152,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:观察大剂量复方苦参注射液联合吉西他滨+卡铂(GC)化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将90例确诊的晚期NSCLC患者以随机抽样法分为治疗组50例和对照组40例,治疗组采用大剂量复方苦参注射液联合GC方案化疗,28 d为1个周期,连用2个周期;对照组应用GC方案化疗,观察实体瘤近期疗效、疼痛程度缓解、生活质量变化、不良反应等情况。结果:治疗组疼痛缓解程度明显优于对照组,近期疗效及生活质量改善方面,治疗组较对照组高;2组不良反应比较,除血红蛋白计数下降差异无统计学意义(P>0.05)外,其余指标治疗组均低于对照组。结论:大剂量复方苦参注射液联合GC化疗具有明显减轻癌性疼痛、增强疗效、改善生存质量、减轻化疗不良反应的作用。OBJECTIVE： To evaluate the curative efficacy of large dose of compound matrine injection combined GC chemotherapy（gemcitabine＋cisplatin） for non-small-cell lung cancer（NSCLC）.METHODS： A total of 90 NSCLC patients were randomly assigned to receive either compound matrine injection plus GC chemotherapy for two cycles（with 28 days defined as 1 cycle）（treatment group,n=50） or GC chemotherapy alone（control group,n=40）.The short-term efficacy on solid tumor,pain relief degree,quality of life and adverse drug reactions were followed.RESULTS： The treatment group showed significantly better improvement in pain relief and short-term efficacy than did control group;with regard to adverse drug reactions,except hemoglobin reduction which showed no significant differences（P0.05）,all the other indexes were lower in the treatment group than in the control group.CONCLUSION： Addition of large dose of compound matrine injection to chemotherapy for NSCLC can significantly relieve cancerous pain,improve curative efficacy,improve the quality of life and attenuate the adverse reaction of chemotherapy.

关 键 词：复方苦参注射液 非小细胞肺癌 化疗 

分 类 号：R979.1[医药卫生—药品]